# The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients

> **NCT05938712** · PHASE2 · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 20 (estimated)

## Conditions studied

- Kidney Transplant Recipients

## Interventions

- **DRUG:** Dapagliflozin 10 MG
- **DRUG:** Semaglutide, 1.0 mg/mL

## Key facts

- **NCT ID:** NCT05938712
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-24
- **Primary completion:** 2027-10-01
- **Final completion:** 2028-03-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05938712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05938712, "The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05938712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*